AI Article Synopsis
- - The IL-17 pathways play a key role in inflammatory skin conditions, especially hidradenitis suppurativa, which currently has adalimumab as the only FDA-approved treatment.
- - Secukinumab, an IL-17A inhibitor, has been effective for conditions like psoriasis and shows promising results for hidradenitis suppurativa in recent phase III clinical trials.
- - This article explores how secukinumab works and reviews its clinical efficacy and safety for managing hidradenitis suppurativa.
Article Abstract
The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab, an IL-17A inhibitor, has been used for years in inflammatory skin disorders such as psoriasis. To date, the only US FDA-approved medication for hidradenitis suppurativa is adalimumab, a TNF-α inhibitor. Recently, secukinumab has demonstrated promising results in the treatment of hidradenitis suppurativa in the phase III SUNSHINE and SUNRISE clinical trials. This article reviews the mechanism of action of secukinumab and summarizes the available clinical efficacy and safety data regarding secukinumab in the management of hidradenitis suppurativa.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2023-0103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Upregulation of TLR2 in keratinocytes activates the MAPK pathway and plays a role in the pathogenesis of hidradenitis suppurativa.
J Dermatol Sci
November 2024
Department of Dermatology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:
Background: Mutations in gamma-secretase complex (GSC) genes are associated with hidradenitis suppurativa (HS), and toll-like receptor (TLR) 2 is elevated in HS lesions. However, it remains unclear whether TLR2 is upregulated in the skin lesions of patients with HS with GSC gene variants, and the role of its upregulation in the pathogenesis of this disease are unknown.
Objective: To investigate the role of TLR2 upregulation in NCSTN and PSENEN knockdown keratinocytes.
Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study.
J Pers Med
December 2024
Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.
the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98.
View Article and Find Full Text PDFBackground: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist.
Objective: To provide evidence-based consensus recommendations for patients with HS in seven special patient populations: i) pregnancy, ii) breastfeeding, iii) pediatrics, iv) malignancy, v) tuberculosis infection, vi) hepatitis B or C infection, and vii) HIV disease.
The influence of hormonal combined contraceptive in the onset of hidradenitis suppurativa: a retrospective cohort study.
Clin Exp Dermatol
December 2024
Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease characterized by recurrent painful nodules, abscesses and sinus tract on the apocrine gland-bearing skin. The role of sex hormones in the pathogenesis as well as the use of hormonal treatment in the management of HS is still debated. We performed a retrospective cohort study including 183 patients to assess the influence of combined estrogen-progestin oral contraceptive (COC) in HS onset and disease severity.
View Article and Find Full Text PDFReply: Update on Ultrasound Diagnostic Criteria and New Ultrasound Severity and Activity Scorings of Hidradenitis Suppurativa: Modified SOS-HS and US-HAS.
J Ultrasound Med
December 2024
AST Ancona, Ospedale di Comunità Maria Montessori di Chiaravalle, Ancona, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!